Human growth hormone has a clinical evidence base for adults with documented deficiency. Changes in body composition seen during replacement are not proof of meaningful strength gains or acceptable risks in healthy users.
Key points
- Treating documented deficiency differs fundamentally from non-medical use.
- Lean-mass measures can reflect fluid changes as well as tissue changes.
- Healthy-adult performance outcomes require separate assessment from replacement outcomes.
What the literature shows
Hoffman and colleagues studied replacement in adults with growth-hormone deficiency in a controlled trial; body composition improved relative to placebo in this defined population. It cannot establish an advantage in people without deficiency.
A systematic review and meta-analysis of growth-hormone administration in healthy young adults considered muscle mass and strength separately. Measured body-composition changes should not automatically be equated with increased functional performance.
What remains unknown
- Long-term consequences of non-medical use, especially alongside other drugs, are incompletely studied.
- Whether a measured change in fat-free mass represents useful muscle gain depends on study methods and context.
Safety and monitoring implications
- Fluid retention, joint symptoms and metabolic changes merit clinical assessment.
- Growth-factor manipulation should not be treated as a low-risk alternative to anabolic steroids.
Cited literature
- 1.Hoffman AR, Kuntze JE, Baptista J, et al. (2004). Growth hormone replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. Journal of Clinical Endocrinology & Metabolism. Find on PubMed
- 2.Sergeeva YM, Miroshnikov AB, Smolensky AV, et al. (2019). Effect of growth hormone administration on the mass and strength of muscles in healthy young adults: a systematic review and meta-analysis. Human Physiology. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Editorial evidence status
MixedNo independently verified community reports were available for this analysis. Anecdotes have not been invented or treated as clinical evidence.
Buying Recombinant human growth hormone in Australia: what to check first
APEDRA does not sell Recombinant human growth hormone or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.